PORTAL VEIN THROMBOSIS AS A COMPLICATION OF COVID-19 IN A PATIENT WITH EPSTEIN-BARR VIRUS/CYTOMEGALOVIRUS INFECTION
Abstract
Portal vein thrombosis is a partial or complete occlusion of blood flow through the portal vein, resulting from the presence of a thrombus in its lumen. The etiology of portal vein thrombosis is often multifactorial, a combination of local and systemic factors being possible. It is necessary to conduct a wide diagnostic search in order to identify the causes
of thrombosis, including liver diseases, malignant neoplasms, infectious diseases, etc. The clinical picture of portal vein thrombosis can vary from low-symptomatic manifestations to an acute course. Chronic portal vein thrombosis can also manifest with nonspecific symptoms. It is known that COVID-19 is associated with increased blood clotting and the development of thromboembolic complications. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is considered as a trigger factor for the reactivation mechanisms of other viral infections in the patient's body, in particular the herpes group. This article presents a clinical case of COVID-19, complicated by portal vein thrombosis in a patient with EBV/CMV infection.
References
Luzina EV, Tomina EV, Shhadneva SI, Lazareva NV. Tromboz vorotnoj veny - obzor literatury i sobstvennye klinicheskie nabljudenija [Portal vein thrombosis - a literature review and our own clinical observations]. Jeksperimentalnaja i klinicheskaja gastrojenterologija [Experimental and Clinical Gastroenterology Journal]. 2020;9(181):55-62. https://doi.org/10.31146/1682-8658-ecg-181-9-55-62 (Russian).
European Association for the Study of the Liver. Clinical guidelines for EASL: vascular disease of the liver. Journal of Hepatology. 2016;64(1):179-202. https://doi.org/10.1016/j.jhep.2015.07.040
Nikitin IG, Il'chenko LJu, Fedorov IG, Totoljan GG. Porazhenie pecheni pri COVID-19: dva klinicheskih nabljudenija [Liver injury in COVID-19: two clinical cases]. Almanah klinicheskoj mediciny [Almanac of Clinical Medicine]. 2020;48(6):412-421. https://doi.org/10.18786/2072-0505-2020-48-053 (Russian).
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports. 2020;2(3):100113. https://doi.org/10.1016/j.jhepr.2020.100113
Trisko AA. Optimizacija diagnosticheskih i prognosticheskih kriteriev infekcionnogo mononukleoza jepshtejna-barr-virusnoj jetiologii u vzroslyh [master's thesis]. Moskva (Russian); 2017. 24 р. (Russian).
Solomaj TV, Semenenko TA, Isaeva EI, Vetrova EN, Chernyshova AI, Romenskaja JeV, Karazhas NV. COVID-19 i risk reaktivacii gerpesvirusnoj infekcii. [COVID-19 and the risk of herpesvirus reactivation]. Jepidemiologija i infekcionnye bolezni. Aktual'nye voprosy [Epidemiology and infectious diseases. Сurrent items]. 2021;11(2):55-62. https://doi.org/10.18565/epidem.2021.11.2.55-62 (Russian).
Solomaj TV, Semenenko TA, Filatov NN, Vedunova SL, Lavrov VF, Smirnova DI, Grachjova AV, Fajzuloev EB. Reaktivacija infekcii, vyzvannoj virusom Jepshtejna-Barr (Herpesviridae: Lymphocryptovirus, HHV-4), na fone COVID-19: jepidemiologicheskie osobennosti [Reactivation of Epstein-Barr virus (Herpesviridae: Lymphocryptovirus, HHV-4) infection during covid-19: epidemiological features]. Voprosy virusologii [Problems of Virology]. 2021;66(2):152-161. https://doi.org/10.36233/0507-4088-40. (Russian).
1.png)
